A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery, and/or radiation therapy.
The purpose of this study is to compare the effect of aspirin (300 mg daily) versus placebo upon invasive disease free survival (iDFS) in early stage node-positive HER2 negative breast cancer patients.
- IRB Number: 1701922942 (A011502)
- Research Study Identifier: TX7374
- Principal Investigator: Kathy Miller, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required